STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Other Events

ME Staff 8-k
-
0
STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Other Events

STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Other Events
Item 8.01. Other Events.

On August15, 2018, Strongbridge Biopharma plc (the “Company”) issued a press release entitled “Strongbridge Biopharma plc Announces Termination of Public Offering,” a copy of which is hereby filed as Exhibit99.1 and is incorporated herein by reference. The termination results from an assessment by the Company’s management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company’s shareholders. As a result of such termination, no shares will be sold to the offering.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.


Strongbridge Biopharma plc Exhibit
EX-99.1 2 a18-18912_1ex99d1.htm EX-99.1 Exhibit 99.1   Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares   DUBLIN,…
To view the full exhibit click here

About STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP)

Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing’s syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.